Irisin attenuates myocardial ischemia/reperfusion‐induced cardiac dysfunction by regulating ER‐mitochondria interaction through a mitochondrial ubiquitin ligase‐dependent mechanism. Issue 5 (14th September 2020)

• Record Type: Journal Article
• Authors: Lu, Linhe; Ma, Jipeng; Tang, Jiayou; Liu, Yang; Zheng, Qijun; Chen, Shasha; Gao, Erhe; Ren, Jun; Yang, Lifang; Yang, Jian
• Is Part Of: Clinical and translational medicine. Volume 10:Issue 5(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-09-14
• Subjects: apoptosis -- endoplasmic reticulum stress -- irisin (FNDC5) -- mitochondrial ubiquitin ligase (MITOL) -- myocardial ischemia/reperfusion (MI/R) -- reactive oxygen species (ROS); Clinical medicine -- Periodicals; Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 616.027
• DOI: 10.1002/ctm2.166
• Languages: English
• ISSNs: 2001-1326

Abstract

Abstract: Background: Myocardial ischemia/reperfusion (MI/R) injury imposes devastating cardiovascular sequelae in particular cardiac dysfunction as a result of restored blood flow. However, the mechanism behind MI/R injury remains elusive. Mitochondrial ubiquitin ligase (MITOL/MARCH5) is localized at the mitochondria‐ER contact site and may be activated in response to a variety of pathophysiological processes, such as apoptosis, mitochondrial injury, ER stress, hypoxia, and reactive oxygen species (ROS) generation. Irisin as a cleaved product of fibronectin type III domain‐containing protein 5 (FNDC5) displays cardioprotection in diverse cardiac diseases. Methods: This study was designed to examine the role of irisin and MITOL in MI/R injury. Male C57BL/6J mice (8‐10‐week‐old) were administered adenovirus MITOL shRNA through intracardiac injection followed by MI/R surgery through ligation and release the slipknot of cardiac left anterior descending coronary artery. Results: Our results showed that irisin improved myocardial function in the face of MI/R injury as evidenced by reduced myocardial infarct size, apoptotic rate, serum lactate dehydrogenase (LDH), ROS generation, and malondialdehyde (MDA) levels as well as lessened ER stress injury. Moreover, our results indicated that protective role of irisin was mediated by upregulation of MITOL. Irisin also protected H9c2 cells against simulated I/R through negating ER stress, apoptosis, ROS and MDA levels, as well as facilitating superoxide dismutase (SOD) by way of elevated MITOL expression. Conclusions: To this end, our data favored that irisin pretreatment protects against MI/R injury, ER stress, ROS production, and mitochondrial homeostasis through upregulation of MITOL. These findings depicted the therapeutic potential of irisin and MITOL in the management of MI/R injury in patients with ST‐segment elevation. Abstract : Irisin improves cardiac function against myocardial ischemia/reperfusion (MI/R) injury, decreases apoptosis and myocardial infarct size following MI/R injury, alleviates reactive oxygen species (ROS) production following MI/R injury, and protects against MI/R injury, ER stress, and mitochondrial homeostasis through upregulation of MITOL